Company intelligence / Profile preview

Gynesonics

Redwood City, California, United Statesgynesonics.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

The Sonata System has been clinically proven to reduce symptoms of uterine fibroids through a minimally invasive, incisionless transcervical procedure. It combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation. The system preserves the uterus and offers an alternative to hysterectomy or myomectomy for a broad range of fibroid types and sizes. It has reached significant patient milestones globally.

Therapeutic areas: Women's Health
Modalities: DeviceRadiofrequency ablation deviceUltrasound-guided therapy
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Sonata System

Commercial

Indications: Uterine fibroids, Heavy menstrual bleeding

Beyond the preview

Go deeper on Gynesonics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gynesonics.

Explore the full profile